. 2020 Apr 1;27(Suppl 2):S78–S86. doi: 10.3747/co.27.5183

TABLE II.

Randomized trials of immune checkpoint inhibitors in previously treated advanced non-small-cell lung cancer

Reference (trial name)	Enrolment period	Treatment arms	Pts (n)	Median OS			Grade 3 or greater treatment-related adverse events (%)

				(months)	HR	CI
Brahmer et al., 2015²³ (CheckMate 057, nonsquamous)	2012–2013	Nivolumab	287	12.2	0.73	96%: 0.59 to 0.89	10
Brahmer et al., 2015²³ (CheckMate 057, nonsquamous)		Docetaxel	268	9.4		96%: 0.59 to 0.89	54

Herbst et al., 2016²⁶ (OAK, all)	2014–2015	Atezolizumab	425	13.8	0.73	95%: 0.62 to 0.87	15
Herbst et al., 2016²⁶ (OAK, all)		Docetaxel	425	9.6		95%: 0.62 to 0.87	43

Horn et al., 2017²⁵ (KEYNOTE-010, PD-L1≥1%)	2013–2015	Pembrolizumab 2 mg/kg	345	10.4			13
		Pembrolizumab 10 mg/kg	346	12.7			16
		Docetaxel	343	8.5			35

Rittmeyer et al., 2017²⁷ (JAVELIN Lung 200, PD-L1≥1%)	2015–2017	Avelumab	264	11.4	0.90	96%: 0.72 to 1.12	10
Rittmeyer et al., 2017²⁷ (JAVELIN Lung 200, PD-L1≥1%)		Docetaxel	265	10.3		96%: 0.72 to 1.12	49

Huang et al., 2018²² (CheckMate 017, squamous)	2012–2013	Nivolumab	135	9.2	0.59	95%: 0.44 to 0.79	7
Huang et al., 2018²² (CheckMate 017, squamous)		Docetaxel	137	6.0		95%: 0.44 to 0.79	57

HR = hazard ratio; CI = confidence interval.